Proteinea is making a name for itself in the fast-growing world of biotherapeutics. An integral part of modern medicine, biotherapeutic medicines, including monoclonal antibodies and other novel protein-based modalities, are used to treat everything from arthritis to cancer with extreme precision and lower side effects. They currently account for nearly one-half of new drug approvals.
Proteinea founders Mahmoud Eljendy and Abdulaziz Elgammal saw an opportunity to create a smarter, faster and safer protein engineering platform. Founded in Cairo, Egypt in early 2020, Proteinea later joined KAUST as part of the Destination Deep Tech – a three-month program that provides deep tech startups resources, infrastructure and mentoring to explore opportunities in Saudi Arabia. Proteinea leveraged its experience with the program to advance its R&D footprint and join the vibrant research and deep tech community.
Read the full news post
0 Comments